SEMENTIS
Sementis is an Australian unlisted public biotechnology company that is using its proprietary SCV platform. The Company is using its proprietary Sementis Copenhagen Vector (SCV) platform technology to generate a portfolio of innovative vaccine candidates for the prevention of allergies and infectious diseases. SCV is a novel vector platform that uses a replication-incompetent vaccinia virus to stimulate both B-cell and T-cell immune responses. The genes for disease antigens are added to the SCV, which upon inoculation elicits a potent immune response to the disease state.
SEMENTIS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2011-01-01
Address:
Melbourne, Victoria, Australia
Country:
Australia
Website Url:
http://www.sementis.com.au
Total Employee:
1+
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon WordPress Google Universal Analytics Mobile Non Scaleable Content
Current Employees Featured
Official Site Inspections
http://www.sementis.com.au Semrush global rank: 5.46 M Semrush visits lastest month: 1.56 K
- Host name: 172.67.154.165
- IP address: 172.67.154.165
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Sementis"
Company - Sementis
About Sementis. Sementis is an Australian unlisted public biotechnology company based in Adelaide, South Australia that is dedicated to the research and development of new vaccines to tackle the world’s most challenging diseases. …See details»
Sementis
Vaccines are a key solution to healthcare system sustainability and disease reduction Traditionally vaccines can take years to development. As the COVID …See details»
About - Sementis
Sementis was founded in 2009, based on the invention of the SCV platform system. This technology combines a viral vector genetically engineered for safety with a commercial …See details»
Sementis Ltd - LinkedIn
Sementis Ltd is an Australian unlisted public biotechnology company based in Adelaide, South Australia and dedicated to research and development of new vaccines to tackle viruses and diseases ...See details»
Sementis Ltd: Contact Details and Business Profile
Sementis Ltd is an Australian unlisted public biotechnology company based in Adelaide, South Australia and dedicated to research and development of new vaccines to tackle viruses and …See details»
Sementis - Crunchbase Company Profile & Funding
Sementis is an Australian unlisted public biotechnology company that is using its proprietary SCV platform. The Company is using its proprietary Sementis Copenhagen Vector (SCV) platform technology to generate a portfolio of …See details»
Sementis - Overview, News & Similar companies | ZoomInfo.com
Nov 5, 2018 Sementis is an Australian unlisted public biotechnology company that is using its proprietary Sementis Copenhagen Vector (SCV) platform technology to generate a portfolio of …See details»
Sementis Ltd Overview | SignalHire Company Profile
Organization Website: sementis.com.au : Sementis Ltd industries Biotech: Headquarters Location: 25 North Terrace, Hackney, South Australia, 5069 AU 25 North Terrace, Hackney, ...See details»
Sementis Ltd - AusBiotech
Sementis Ltd is developing a novel vaccine platform designed to deliver new vaccines and immunotherapies to the world’s most challenging and complex diseases by unlocking the …See details»
SEMENTIS LIMITED Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for SEMENTIS LIMITED of HACKNEY, SOUTH AUSTRALIA. Get the latest business insights from Dun & …See details»
Technology - Sementis
Sementis was founded in 2009 with the aim to improve on the MVA-BN viral vector and the overall success of vaccinia vectors by overcoming: Manufacturability (complexity, scale, and lead times) Perceived …See details»
Current details for ABN 36 138 550 811 - ABN Lookup
SEMENTIS LIMITED: ABN status: Active from 29 Jul 2009 Entity type: Australian Public Company: Goods & Services Tax (GST): Registered from 29 Jul 2009 Main business location: …See details»
Sementis Company Profile - Office Locations, Competitors ... - Craft
Sementis is a biotechnology company using its proprietary SCV platform technology to generate vaccine candidates for the prevention of infectious diseases and the treatment of immune …See details»
Sementis - Startup Galaxy
Sementis Ltd is an Australian unlisted public biotechnology company based in Adelaide, South Australia and dedicated to research and development of new vaccines to tackle viruses and …See details»
Key steps to advance vaccine manufacturing technology
Dec 8, 2022 The SCV platform from Sementis combines a non-replicating viral vector with a genetically modified commercial manufacturing cell line, to realise an efficient and effective …See details»
New leadership for vaccine platform technology company Sementis
Sep 14, 2023 Sementis owns an advanced vaccine platform technology and a portfolio of candidates in development. It has government grant funding and key institutional partnerships …See details»
Australian biotech company advancing vaccine manufacture
Dec 20, 2022 Emerging Australian biotech company Sementis is engaging with Health Security Systems Australia and Australian universities to enhance the ability of its existing vaccine …See details»
Pipeline - Sementis
Sementis’ SCV-Peanut Hypoallergenic Vaccine (SCV-PHAV) immunotherapy is designed to induce a long-lived immune response to tolerate peanut allergens. It can potentially address …See details»
Sementis clears path for $10 million investment into COVID
Aug 4, 2021 Adelaide biotech company Sementis has been given the all-clear to raise up to $10 million to develop its next-generation COVID-19 vaccine amid concerns the rights issue could …See details»
Biotech firm seeks to raise $10 million to progress its Covid-19 ...
03 August 2021 Professor John Hayball. Adelaide-based biotechnology company Sementis is seeking to raise up to $10 million from its shareholders to accelerate work on its next …See details»